DexCom (NASDAQ:DXCM) PT Lowered to $105.00

DexCom (NASDAQ:DXCM) had its price objective cut by analysts at Oppenheimer from $115.00 to $105.00 in a research report issued on Friday, Benzinga reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. Oppenheimer’s target price points to a potential upside of 39.55% from the stock’s current price.

DXCM has been the topic of several other reports. Leerink Partners dropped their price objective on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday. Wells Fargo & Company raised their price objective on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday. BTIG Research dropped their price objective on DexCom from $156.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, July 26th. Baird R W lowered DexCom from a “strong-buy” rating to a “hold” rating in a report on Friday, July 26th. Finally, Royal Bank of Canada dropped their price objective on DexCom from $130.00 to $120.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Seven analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.88.

DexCom Stock Performance

DexCom stock traded up $0.39 during midday trading on Friday, hitting $75.24. 7,176,765 shares of the company were exchanged, compared to its average volume of 3,866,473. The firm has a market capitalization of $29.92 billion, a PE ratio of 48.54, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The business has a fifty day simple moving average of $70.13 and a two-hundred day simple moving average of $98.71. The company has a debt-to-equity ratio of 1.00, a quick ratio of 2.48 and a current ratio of 2.82.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, October 24th. The medical device company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $994.20 million for the quarter, compared to analyst estimates of $991.55 million. On average, sell-side analysts forecast that DexCom will post 1.69 earnings per share for the current year.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other DexCom news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at $4,607,617.95. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,824 shares of company stock worth $126,390. 0.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On DexCom

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Team Hewins LLC raised its stake in DexCom by 3.4% during the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after acquiring an additional 83 shares during the last quarter. Bleakley Financial Group LLC raised its stake in DexCom by 1.3% during the 1st quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after acquiring an additional 87 shares during the last quarter. Capital Insight Partners LLC raised its stake in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after acquiring an additional 90 shares during the last quarter. HM Payson & Co. increased its position in DexCom by 6.0% during the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock worth $247,000 after purchasing an additional 100 shares during the period. Finally, State of Alaska Department of Revenue increased its position in DexCom by 0.3% during the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock worth $5,801,000 after purchasing an additional 105 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.